Fennec Pharmaceuticals to Join Piper Sandler Conference
Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX), a leading specialty pharmaceutical company, has announced its participation in a prominent healthcare event this upcoming December. The company plans to hold a fireside chat during the Piper Sandler 37th Annual Healthcare Conference, which will be available for webcast. This conference offers an exceptional platform for Fennec to discuss its innovative approaches in addressing ototoxicity in cancer patients.
Webcast and Conference Details
The announcement includes key details about the upcoming webcast. On December 3, attendees can tune in at 1:00 p.m. ET to hear from Fennec’s management team. This live event will allow cancer care stakeholders and interested listeners to learn more about the company's mission and products. A link to the webcast will be shared ahead of the event, ensuring easy access for those who want to participate.
What to Expect from the Chat
During the fireside chat, attendees can expect insightful discussions surrounding Fennec's efforts to mitigate the risks of ototoxicity associated with cisplatin therapy in pediatric patients. The conversation aims to shed light on how the company's flagship product, PEDMARK, plays a critical role in this area.
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals is dedicated to combating the significant challenges posed by ototoxicity in patients undergoing cisplatin-based chemotherapy. The company's leading product, PEDMARK, is geared toward minimizing this risk. PEDMARK gained FDA approval in late 2022, followed closely by approvals in Europe and the United Kingdom, demonstrating Fennec's strong commitment to improving patient outcomes.
Recent Developments and Partnerships
Recently, in early 2024, Fennec announced an exclusive licensing agreement with Norgine Pharmaceuticals Ltd., allowing them to commercialize PEDMARQSI in various international markets including Europe, the U.K., Australia, and New Zealand. This partnership is indicative of Fennec's exponential reach and rapid growth in the specialty pharmaceuticals sector.
Market Position and Patient Impact
The company holds significant patents that ensure the protection of PEDMARK until 2039, allowing them to maintain a competitive edge. The products have received Orphan Drug Exclusivity in the U.S. and impressive market protections in Europe, including Pediatric Use Marketing Authorization. These accolades underscore Fennec's dedication to improving treatment standards for pediatric oncology patients.
Stay Informed with Fennec Pharmaceuticals
For more information on Fennec Pharmaceuticals and their product offerings, stakeholders are encouraged to visit their official website. The company's continuous updates and insights into their research and initiatives make it an important resource for interested parties.
Contact Information
If you would like further details, Fennec has provided contact information for investor relations and media inquiries:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
Frequently Asked Questions
What is the significance of the Piper Sandler Conference for Fennec?
This conference allows Fennec to showcase their innovative products and connect with healthcare stakeholders.
When will the fireside chat take place?
The fireside chat is scheduled for December 3 at 1:00 p.m. ET, with details available prior to the event.
What is PEDMARK and its importance?
PEDMARK is Fennec's product designed to reduce the risk of ototoxicity in pediatric cancer patients receiving cisplatin.
Who is partnering with Fennec for international marketing?
Norgine Pharmaceuticals Ltd. has signed an exclusive licensing agreement to commercialize PEDMARQSI in multiple countries.
How can investors keep track of Fennec's progress?
Investors can stay updated by visiting the company's website for the latest news and updates regarding their initiatives and products.